Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P41002: Variant p.Ser621Gly

Cyclin-F
Gene: CCNF
Feedback?
Variant information Variant position: help 621 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Serine (S) to Glycine (G) at position 621 (S621G, p.Ser621Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and polar (S) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In FTDALS5; increased 'Lys-48'-linked polyubiquitination of proteins targeted for proteasomal degradation, but no increase in 'Lys-63'-linked polyubiquitinated proteins; accumulation of ubiquitinated proteins including RRM2 and TARDBP/TDP43; impaired autophagosome-lysosome fusion; impaired degradation by the ubiquitin proteasome system (UPS); increased levels of ubiquitinated autophagy receptor SQSTM1/p62. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 621 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 786 The length of the canonical sequence.
Location on the sequence: help LGSFLDWSLDCCSGYEGDQE S EGEKEGDVTAPSGILDVTVV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         LGSFLDWSLD-CCSGYEGDQESEGEKEGDVTAPSGILDVTVV

Mouse                         LGSLLDWSLE-CCSGYEGDQESEGEKEGDVTAPSRLLDVTV

Rat                           LGSLLDWSLD-CCSGYEGDQESEGEKEGDVTAPSGLLDVTV

Bovine                        LGSFLDWSLD-YCSGYEGDQESEGEKEGDVTAPSGVLDVTV

Xenopus laevis                LGDFLDWSLETSCSGYEGDRESEGEREGEVTAPSGVLDLSL

Xenopus tropicalis            LGDFLDWSLETSCSGYEGDRESEGEREGEVTAPSGVLDLSL

Zebrafish                     LGDFLDWSLDTSCSGYEGDRESEGEKDGEISTMEVQMELPL
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 786 Cyclin-F
Region 582 – 766 PEST



Literature citations
CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia.
Williams K.L.; Topp S.; Yang S.; Smith B.; Fifita J.A.; Warraich S.T.; Zhang K.Y.; Farrawell N.; Vance C.; Hu X.; Chesi A.; Leblond C.S.; Lee A.; Rayner S.L.; Sundaramoorthy V.; Dobson-Stone C.; Molloy M.P.; van Blitterswijk M.; Dickson D.W.; Petersen R.C.; Graff-Radford N.R.; Boeve B.F.; Murray M.E.; Pottier C.; Don E.; Winnick C.; McCann E.P.; Hogan A.; Daoud H.; Levert A.; Dion P.A.; Mitsui J.; Ishiura H.; Takahashi Y.; Goto J.; Kost J.; Gellera C.; Gkazi A.S.; Miller J.; Stockton J.; Brooks W.S.; Boundy K.; Polak M.; Munoz-Blanco J.L.; Esteban-Perez J.; Rabano A.; Hardiman O.; Morrison K.E.; Ticozzi N.; Silani V.; de Belleroche J.; Glass J.D.; Kwok J.B.; Guillemin G.J.; Chung R.S.; Tsuji S.; Brown R.H. Jr.; Garcia-Redondo A.; Rademakers R.; Landers J.E.; Gitler A.D.; Rouleau G.A.; Cole N.J.; Yerbury J.J.; Atkin J.D.; Shaw C.E.; Nicholson G.A.; Blair I.P.;
Nat. Commun. 7:11253-11253(2016)
Cited for: INVOLVEMENT IN FTDALS5; VARIANTS FTDALS5 GLY-3; ARG-97; ILE-181; ARG-195; THR-392; PRO-509; ILE-543; GLY-621; LYS-624 AND THR-772; CHARACTERIZATION OF VARIANTS FTDALS5 GLY-3; ARG-97; ARG-195; THR-392; PRO-509; GLY-621; LYS-624 AND THR-772; FUNCTION; Pathogenic mutation in the ALS/FTD gene, CCNF, causes elevated Lys48-linked ubiquitylation and defective autophagy.
Lee A.; Rayner S.L.; Gwee S.S.L.; De Luca A.; Shahheydari H.; Sundaramoorthy V.; Ragagnin A.; Morsch M.; Radford R.; Galper J.; Freckleton S.; Shi B.; Walker A.K.; Don E.K.; Cole N.J.; Yang S.; Williams K.L.; Yerbury J.J.; Blair I.P.; Atkin J.D.; Molloy M.P.; Chung R.S.;
Cell. Mol. Life Sci. 75:335-354(2018)
Cited for: CHARACTERIZATION OF VARIANT FTDALS5 GLY-621; FUNCTION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.